Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

367 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Targeting the DNA Damage Response in Cancer.
O'Connor MJ. O'Connor MJ. Mol Cell. 2015 Nov 19;60(4):547-60. doi: 10.1016/j.molcel.2015.10.040. Mol Cell. 2015. PMID: 26590714 Review.
The overexpression of specialized DNA polymerases in cancer.
Albertella MR, Lau A, O'Connor MJ. Albertella MR, et al. DNA Repair (Amst). 2005 May 2;4(5):583-93. doi: 10.1016/j.dnarep.2005.01.005. DNA Repair (Amst). 2005. PMID: 15811630
A role for polymerase eta in the cellular tolerance to cisplatin-induced damage.
Albertella MR, Green CM, Lehmann AR, O'Connor MJ. Albertella MR, et al. Cancer Res. 2005 Nov 1;65(21):9799-806. doi: 10.1158/0008-5472.CAN-05-1095. Cancer Res. 2005. PMID: 16267001
hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage.
Moumen A, Masterson P, O'Connor MJ, Jackson SP. Moumen A, et al. Cell. 2005 Dec 16;123(6):1065-78. doi: 10.1016/j.cell.2005.09.032. Cell. 2005. PMID: 16360036
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.
McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A. McCabe N, et al. Cancer Res. 2006 Aug 15;66(16):8109-15. doi: 10.1158/0008-5472.CAN-06-0140. Cancer Res. 2006. PMID: 16912188
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.
Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, Holstege H, Liu X, van Drunen E, Beverloo HB, Smith GC, Martin NM, Lau A, O'Connor MJ, Jonkers J. Evers B, et al. Clin Cancer Res. 2008 Jun 15;14(12):3916-25. doi: 10.1158/1078-0432.CCR-07-4953. Clin Cancer Res. 2008. PMID: 18559613
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J. Rottenberg S, et al. Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84. doi: 10.1073/pnas.0806092105. Epub 2008 Oct 29. Proc Natl Acad Sci U S A. 2008. PMID: 18971340 Free PMC article.
Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.
Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AO, Douglas-Jones A, Smith GC, Martin NM, O'Connor M, Clarke AR. Hay T, et al. Cancer Res. 2009 May 1;69(9):3850-5. doi: 10.1158/0008-5472.CAN-08-2388. Epub 2009 Apr 21. Cancer Res. 2009. PMID: 19383921
ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.
Williamson CT, Muzik H, Turhan AG, Zamò A, O'Connor MJ, Bebb DG, Lees-Miller SP. Williamson CT, et al. Mol Cancer Ther. 2010 Feb;9(2):347-57. doi: 10.1158/1535-7163.MCT-09-0872. Epub 2010 Feb 2. Mol Cancer Ther. 2010. PMID: 20124459 Free PMC article.
Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control.
Golding SE, Rosenberg E, Adams BR, Wignarajah S, Beckta JM, O'Connor MJ, Valerie K. Golding SE, et al. Cell Cycle. 2012 Mar 15;11(6):1167-73. doi: 10.4161/cc.11.6.19576. Epub 2012 Mar 15. Cell Cycle. 2012. PMID: 22370485 Free PMC article.
367 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback